Results of a hepatitis C general transfusion lookback program for patients who received blood products before July 1992

Transfusion

Volumn 45, Issue 6, 2005, Pages 1020-1026

  Williams, James L ^a,b   Cagle, Henry H ^a   Christensen, Carol J ^a   Fox Leyva, Leslie K ^a   McMahon, Brian J ^a  

^a Office of Community Health   (United States)

^b ANC HEP   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

HEPATITIS C ANTIBODY; VIRUS RNA;

ARTICLE; BLOOD SAMPLING; BLOOD TRANSFUSION; COST BENEFIT ANALYSIS; DATA BASE; HEALTH CARE COST; HEALTH PROGRAM; HEPATITIS C; HEPATITIS C VIRUS; HUMAN; INFECTION RISK; MAJOR CLINICAL STUDY; MASS SCREENING; PATIENT COUNSELING; UNITED STATES;

ALASKA; BLOOD TRANSFUSION; COSTS AND COST ANALYSIS; DISEASE NOTIFICATION; DISEASE TRANSMISSION, HORIZONTAL; FEASIBILITY STUDIES; HEPACIVIRUS; HEPATITIS C; HEPATITIS C ANTIBODIES; HUMANS; MASS SCREENING; RETROSPECTIVE STUDIES; RISK FACTORS; RNA, VIRAL; SEROLOGIC TESTS;

EID: 20444406386     PISSN: 00411132     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1537-2995.2005.04280.x     Document Type: Article

References (21)

1. Menitove JE. Rationale for surrogate testing to detect non-A, non-B hepatitis. Transfus Med Rev 1988;2:65-75.
2. Recommendations for prevention and control of hepatitis C virus (HCV) infection and HCV-related chronic disease. Centers for Disease Control and Prevention. MMWR Recomm Rep 1998;47:1-39.
3. Aach RD, Stevens CE, Hollinger FB, et al. Hepatitis C virus in post-transfusion hepatitis: an analysis with first- and second-generation assays. N Engl J Med 1991;325:1325-9.
4. Alter MJ, Kruszon-Moran D, Nainan OV, et al. The prevalance of hepatitis C virus infection in the United States, 1988 through 1994. N Engl J Med 1999;341:556-62.
5. "Guidance for Industry: current good manufacturing practice for blood and blood components. (1) Quarantine and disposition of units from prior collections from donors with repeatedly reactive screening test for antibody to hepatitis C virus (anti-HCV); (2) Supplemental testing, and the notification of consignees and blood recipients of donor test results for anti-HCV;" availability-FDA. Notice. Fed Regist 1998;63:56198-9.
6. Long A, Spurll G, Demers H, Goldman M. Targeted hepatitis C lookback: Quebec, Canada. Transfusion 1999;39:194-200.
7. Culver DH, Alter MJ, Mullan RJ, Margolis HS. Evaluation of the effectiveness of targeted lookback for HCV infection in the United States-interim results. Transfusion 2000;40:1176-81.
8. Transfusion transmission of HCV infection before anti-HCV testing of blood donations in England: results of the national HCV lookback program. Transfusion 2002;42:1146-53.
9. British Columbia Ministry of Health. Report of the blood recipient notification project for hepatitis C: final report. Victoria: Ministry of Health and Ministry Responsible for Seniors; 1998 May.
10. Bowker SL, Smith LJ, Rosychuk RJ, Preiksaitis JK. A review of general hepatitis C virus lookbacks in Canada. Vox Sang 2004;86:21-7.
11. Van Til LD, Sweet LE. Blood recipient notification for hepatitis C in Prince Edward Island. CMAJ 2000;162:199-202.
12. Callum JL, Pinkerton PH, Coovadia AS, Thomson AE, Dewsbury F. An evaluation of the process and costs associated with targeted lookbacks for HCV and general notification of transfusion recipients. Transfusion 2000;40:1169-75.
13. Davoren A, Dillon AD, Power JP, et al. Outcome of an optional HCV screening program for blood transfusion recipients in Ireland. Transfusion 2002;42:1501-6.
14. Hepatitis C counseling and testing manual: the lookback project risk of exposure to blood transfusion or blood products prior to July 1992. Anchorage: Alaska Native Tribal Health Consortium; accessed 2004 Nov 15. Available from: http://www.anthc.org/cs/chs/hep/upload/lookback.doc or http://www.anthc.org/cs/ chs/hep/upload/lookback.pdf
15. Anderson JC, Simonetti JP, Fisher DG, et al. Comparison of different HCV viral load and genotyping assays. J Clin Virol 2003;28:27-37.
16. Bulletin No. 7: Hepatitis C. Anchorage: State of Alaska Epidemiology; 1994 Mar 7 [accessed 2004 Nov 15]. Available from: http://www.epi.hss.state.ak. us/bulletins/docs/b1994_07.htm
17. McMahon BJ, Hennessy TW, Christensen C, et al. Epidemiology and risk factors for hepatitis C in Alaska Natives. Hepatology 2004;39:325-32.
18. Langley JM, Squires SG, MacDonald DM, et al. Evaluation of the notification of hepatitis C risk to children who received unscreened blood or blood products. Commun Dis Public Health 2001;4:288-92.
19. Buffington J, Rowel R, Hinman JM, Sharp K, Choi S. Lack of awareness of hepatitis C risk among persons who received blood transfusions before 1990. Am J Public Health 2001;91:47-8.
20. Pereira A. Health and economic consequences of HCV lookback. Transfusion 2001;41:832-9.
21. Paschane DM, Cagle HH, Fisher DG. Cocaine smokers and injection drug users in Alaska: what distinguishes Native Americans from non-Native Americans? Int J Circumpolar Health 1998;57(Suppl 1):474-81.